AI vs. doctor for anti-VEGF treatment decisions
Part of Eyes & vision, Heart & circulation clinical trials.
This trial compares an AI with a doctor to decide if you need another anti-VEGF injection. You can join if you have wet AMD, diabetic macular edema, or retinal vein occlusion and have finished the first 3 monthly shots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet AMD, diabetic macular edema, or retinal vein occlusion.
- You have already completed the initial 3-month loading dose of anti-VEGF injections.
- You are willing to have an OCT scan (a detailed eye imaging test).
- You agree to come back for checkups over 3 months.
- You have not had any eye surgery in the last 6 months.
- You do not have a severe illness or condition that would affect participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection medicine (AIV007) placed around the eye to treat wet age-related macular degeneration (a condition that damages central vision). You may qualify if you've been treated for this condition before and responded well to previous eye injections.
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
This trial tests whether giving doctors an AI second opinion on retinal scans helps them make better treatment decisions for people with a specific eye disease called nAMD. It's a short, one-time study for eye doctors, not for patients.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.